Evidence map›Paper›PMID 37250639›Full record

ReviewFrontiers in medicine2023

Differential diagnosis of pulmonary sarcoidosis: a review.

Dominique Valeyre, Michel Brauner, Jean-François Bernaudin, Etienne Carbonnelle, Boris Duchemann, Cécile Rotenberg, Ingrid Berger, Antoine Martin, Hilario Nunes, Jean-Marc Naccache and 1 more

Abstract readReview
In one paragraph

Review in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. A case report of pulmonary granuloma misdiagnosed as a malignant tumor.The Journal of international medical research · 2026
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Infectious Complications of Pulmonary Sarcoidosis.Journal of clinical medicine · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dominique ValeyrePulmonology Department, Groupe Hospitalier Paris Saint Joseph, Paris, France.
Michel BraunerRadiology Department, Avicenne University Hospital, Bobigny, France.
Jean-François BernaudinINSERM UMR 1272, Sorbonne University Paris-Nord, Paris, France.
Etienne CarbonnelleMicrobiology Department, Avicenne University Hospital, Bobigny, France.
Boris DuchemannINSERM UMR 1272, Sorbonne University Paris-Nord, Paris, France.
Cécile RotenbergINSERM UMR 1272, Sorbonne University Paris-Nord, Paris, France.
Ingrid BergerPulmonology Department, Groupe Hospitalier Paris Saint Joseph, Paris, France.
Antoine MartinPathology Department, Avicenne University Hospital, Bobigny, France.
Hilario NunesINSERM UMR 1272, Sorbonne University Paris-Nord, Paris, France.
Jean-Marc NaccachePulmonology Department, Groupe Hospitalier Paris Saint Joseph, Paris, France.
Florence JenyINSERM UMR 1272, Sorbonne University Paris-Nord, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diagnosing pulmonary sarcoidosis raises challenges due to both the absence of a specific diagnostic criterion and the varied presentations capable of mimicking many other conditions. The aim of this review is to help non-sarcoidosis experts establish optimal differential-diagnosis strategies tailored to each situation. Alternative granulomatous diseases that must be ruled out include infections (notably tuberculosis, nontuberculous mycobacterial infections, and histoplasmosis), chronic beryllium disease, hypersensitivity pneumonitis, granulomatous talcosis, drug-induced granulomatosis (notably due to TNF-a antagonists, immune checkpoint inhibitors, targeted therapies, and interferons), immune deficiencies, genetic disorders (Blau syndrome), Crohn's disease, granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, and malignancy-associated granulomatosis. Ruling out lymphoproliferative disorders may also be very challenging before obtaining typical biopsy specimen. The first step is an assessment of epidemiological factors, notably the incidence of sarcoidosis and of alternative diagnoses; exposure to risk factors (e.g., infectious, occupational, and environmental agents); and exposure to drugs taken for therapeutic or recreational purposes. The clinical history, physical examination and, above all, chest computed tomography indicate which differential diagnoses are most likely, thereby guiding the choice of subsequent investigations (e.g., microbiological investigations, lymphocyte proliferation tests with metals, autoantibody assays, and genetic tests). The goal is to rule out all diagnoses other than sarcoidosis that are consistent with the clinical situation. Chest computed tomography findings, from common to rare and from typical to atypical, are described for sarcoidosis and the alternatives. The pathology of granulomas and associated lesions is discussed and diagnostically helpful stains specified. In some patients, the definite diagnosis may require the continuous gathering of information during follow-up. Diseases that often closely mimic sarcoidosis include chronic beryllium disease and drug-induced granulomatosis. Tuberculosis rarely resembles sarcoidosis but is a leading differential diagnosis in regions of high tuberculosis endemicity.

Indexed as

differential diagnosisgranulomamicrobiologypathologysarcoidosisthoracic computed tomographytuberculosis

Identifiers

PMID37250639
PMCPMC10213276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.